Decline of Mpox Antibody Responses After Modified Vaccinia Ankara-Bavarian Nordic Vaccination.
作者信息
Collier Ai-Ris Y, McMahan Katherine, Jacob-Dolan Catherine, Liu Jinyan, Borducchi Erica N, Moss Bernard, Barouch Dan H
机构信息
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
出版信息
JAMA. 2024 Nov 19;332(19):1669-1672. doi: 10.1001/jama.2024.20951.
Abstract
摘要
相似文献
1
Decline of Mpox Antibody Responses After Modified Vaccinia Ankara-Bavarian Nordic Vaccination.
JAMA. 2024 Nov 19;332(19):1669-1672. doi: 10.1001/jama.2024.20951.
2
Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
Lancet Infect Dis. 2023 Sep;23(9):1042-1050. doi: 10.1016/S1473-3099(23)00270-0. Epub 2023 Jun 16.
3
Rapid Decline of Mpox Antibody Responses Following MVA-BN Vaccination.
medRxiv. 2024 Sep 11:2024.09.10.24313399. doi: 10.1101/2024.09.10.24313399.
4
Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
Euro Surveill. 2022 Dec;27(50). doi: 10.2807/1560-7917.ES.2022.27.50.2200882.
5
The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response.
J Virol. 2025 Mar 31:e0025325. doi: 10.1128/jvi.00253-25.
6
Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial.
BMJ. 2024 Sep 11;386:e078243. doi: 10.1136/bmj-2023-078243.
7
Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective, single-centre, cohort study and analysis of transcriptomic predictors of response.
Lancet Microbe. 2025 Jun;6(6):101045. doi: 10.1016/j.lanmic.2024.101045. Epub 2025 Apr 23.
8
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.
J Infect Dis. 2023 May 12;227(10):1203-1213. doi: 10.1093/infdis/jiac455.
9
Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox.
JAMA. 2023 Jun 20;329(23):2091-2094. doi: 10.1001/jama.2023.7683.
10
Vaccines against mpox: MVA-BN and LC16m8.
Expert Rev Vaccines. 2024 Jan-Dec;23(1):796-811. doi: 10.1080/14760584.2024.2397006. Epub 2024 Sep 1.
引用本文的文献
1
Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition.
Open Forum Infect Dis. 2025 Aug 14;12(8):ofaf497. doi: 10.1093/ofid/ofaf497. eCollection 2025 Aug.
2
Serological differentiation between naturally acquired mpox and MVA-BN-vaccine induced antibody responses using ratios of MPXV and VACV antigen pairs in the MSD immunoassay.
Microbiol Spectr. 2025 Aug 8:e0018225. doi: 10.1128/spectrum.00182-25.
3
Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model.
Nat Commun. 2025 Aug 7;16(1):7306. doi: 10.1038/s41467-025-62681-2.
4
Molecular detection and isolation of clade Ib monkeypox virus, Canada, November 2024.
Euro Surveill. 2025 Jun;30(25). doi: 10.2807/1560-7917.ES.2025.30.25.2500402.
5
Differences in Mpox and Vaccinia Immunity Induced by Non-Replicating and Replicating Vaccinia-Based Vaccines.
Vaccines (Basel). 2025 May 14;13(5):520. doi: 10.3390/vaccines13050520.
6
Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates.
Nat Commun. 2025 May 21;16(1):4726. doi: 10.1038/s41467-025-59826-8.
7
T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination.
Nat Commun. 2025 May 10;16(1):4362. doi: 10.1038/s41467-025-59370-5.
8
Humoral Immunity Against Orthopoxvirus in Vaccinated and Unvaccinated Individuals during 2022 Mpox Outbreak.
medRxiv. 2025 Mar 17:2025.03.16.25324075. doi: 10.1101/2025.03.16.25324075.
9
Viral introductions and return to baseline sexual behaviors maintain low-level mpox incidence in Los Angeles County, USA, 2023-2024.
medRxiv. 2025 Mar 15:2025.03.14.25323999. doi: 10.1101/2025.03.14.25323999.
10
Approaches to Next-Generation Capripoxvirus and Monkeypox Virus Vaccines.
Viruses. 2025 Jan 27;17(2):186. doi: 10.3390/v17020186.
本文引用的文献
1
Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates.
Cell. 2024 Oct 3;187(20):5540-5553.e10. doi: 10.1016/j.cell.2024.08.043. Epub 2024 Sep 4.
2
WHO Director-General declares mpox outbreak a public health emergency of international concern.
Saudi Med J. 2024 Aug;45(9):1002-1003.
3
Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques.
Sci Transl Med. 2024 Mar 27;16(740):eadl4317. doi: 10.1126/scitranslmed.adl4317.
4
Notes from the Field: Emergence of an Mpox Cluster Primarily Affecting Persons Previously Vaccinated Against Mpox - Chicago, Illinois, March 18-June 12, 2023.
MMWR Morb Mortal Wkly Rep. 2023 Jun 23;72(25):696-698. doi: 10.15585/mmwr.mm7225a6.
5
Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States.
N Engl J Med. 2023 Jun 29;388(26):2434-2443. doi: 10.1056/NEJMoa2215201. Epub 2023 May 18.
6
Update on the Monkeypox Outbreak.
JAMA. 2022 Sep 13;328(10):921-922. doi: 10.1001/jama.2022.14857.
Zotero 插件